Diabetes and Hypertension
Part of NephTimes Diseases and Conditions
Advertisement
A team analyzed sotagliflozin's effects on hemoglobin in patients with stage 3-4 CKD and type 2 diabetes.
Do GLP-1 receptor agonists reduce the risk of important clinical outcomes? Can patients without diabetes benefit from them?
The FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
A secondary analysis of DCP trial data sought to understand the effects of thiazide diuretics on kidney outcomes.
The renal effects and safety of acetazolamide in patients with type 1 diabetes was the subject of a recent study.
A study evaluated kidney outcomes of ARNI therapy versus ACEI/ARB for TMA related to malignant hypertension.
A study examined an association between hyperglycemic crises at diabetes diagnosis and a higher risk of developing CKD.
The accuracy of continuous glucose monitoring versus self-monitored blood glucose in hemodialysis patients is not well known.
Direct comparisons of kidney and cardiovascular outcomes with GLP-1 RAs and SGLT2i in type 2 diabetes are lacking.
Researchers identified risk factors for nonconcordance with CKD screening and treatment guidelines in patients with diabetes.
Having a precise estimation of the costs incurred by DKD patients is an important step in finding ways to contain such costs.
What is the relationship between blood urea nitrogen-to-serum albumin ratio and mortality in ICU patients with T2D and CKD?
A study examined the association between consuming different meats and the odds of developing kidney damage and DN.
Researchers tried to determine whether eGFR slope is a predictor of type 2 diabetes complications.
A study examined the association of HbA1c with mortality in patients with chronic kidney disease and type 2 diabetes.
Researchers conducted an analysis to quantify the within-individual variability of albuminuria in patients with T2D.
A survey found that US physicians would like to find new approaches to lowering patients' blood pressure.
Could urinary podocyte stress biomarker be a surrogate marker of podocyte injury in diabetic kidney disease (DKD)?
There are few data on whether finerenone-induced change in UACR mediates cardiovascular and kidney failure outcomes.
Researchers studied the effect of intensive blood pressure control on the progression of IgAN.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.